Allogeneic bone grafts, whether fresh, frozen, or freeze-dried, have several advantages, including reduced surgical morbidity, shorter operating times, and greater availability and quantity per autogenic bone [1,2]. Histological and histomorphometric results show that allogeneic bone has osteoconductive properties like autogenic bone [3]. The supercritical CO2 (Supercrit ® ) process viral-inactivated allogenic bone grafts (BIOBank, 3, rue Georges Charpak -77127 Lieusaint -France) are derived exclusively from human femoral heads collected from living donors who have
ARTICLE INFO ABSTRACTThis study documents the long-term performance of the Supercrit® viral-inactivated bone allografts in extraction sockets grafting with immediate implant placement. Data were collected from files of 50 patients (29 females, 21 males, mean age of 55.5 years) undergoing immediate implant placement into fresh extraction socket with the supercritical CO2 viral-inactivated allogenic bone grafts (Supercrit® process, BIOBank, Lieusaint, France). 65 implants were placed mainly in the posterior maxilla. At a mean 9.7 years (range: 9 to 10 years), 62 implants were well osseointegrated and functioning. 3 implants failed due to non-osteointegration and were removed 6, 8, and 9-months postsurgery, respectively. The overall implant 10-year survival rate was 95.4% (CI: 90.3 to 100%). The mean marginal bone loss was 0.5 mm (SD:1.6) at the latest follow-up. Within the limitations of this study, the supercritical CO2 viral inactivated bone allograft as a grafting material during immediate implant placement in extraction sockets is a valuable option allowing short treatment time and high long-term implant survival (Figure 1).